Development and validation of peripheral blood DNA methylation signatures to predict response to biological therapy in adults with Crohn's disease (EPIC-CD): an epigenome-wide association study.

Journal: The lancet. Gastroenterology & hepatology
Published Date:

Abstract

BACKGROUND: Biological therapeutics are widely used in Crohn's disease, with evidence of efficacy from randomised trials and real-world experience. Primary non-response is a common, poorly understood problem. We aimed to assess blood methylation as a predictor of response to adalimumab, vedolizumab, or ustekinumab in patients with Crohn's disease.

Authors

  • Vincent W Joustra
    Department of Gastroenterology and Hepatology, Amsterdam University Medical Centre, University of Amsterdam, Amsterdam, Netherlands.
  • Andrew Y F Li Yim
    Tytgat Institute for Liver and Intestinal Research, Amsterdam University Medical Centre, University of Amsterdam, Amsterdam, Netherlands; Genome Diagnostics Laboratory, Department of Human Genetics, Amsterdam University Medical Centre, University of Amsterdam, Amsterdam, Netherlands.
  • Peter Henneman
    Genome Diagnostics Laboratory, Department of Human Genetics, Amsterdam University Medical Centre, University of Amsterdam, Amsterdam, Netherlands.
  • Ishtu Hageman
    Department of Gastroenterology and Hepatology, Amsterdam University Medical Centre, University of Amsterdam, Amsterdam, Netherlands; Tytgat Institute for Liver and Intestinal Research, Amsterdam University Medical Centre, University of Amsterdam, Amsterdam, Netherlands.
  • Tristan de Waard
    Horaizon, Delft, Netherlands.
  • Evgeni Levin
    HORAIZON Technology BV, Delft, The Netherlands. evgeni.levin@horaizon.nl.
  • Alexandra J Noble
    Translational Gastroenterology and Liver Unit, Nuffield Department of Medicine, University of Oxford and NIHR Oxford Biomedical Research Centre, Oxford, UK.
  • Thomas P Chapman
    Translational Gastroenterology and Liver Unit, Nuffield Department of Medicine, University of Oxford and NIHR Oxford Biomedical Research Centre, Oxford, UK; Department of Gastroenterology, St Richard's and Worthing Hospitals, University Hospitals Sussex NHS Foundation Trust, West Sussex, UK.
  • Femke Mol
    Tytgat Institute for Liver and Intestinal Research, Amsterdam University Medical Centre, University of Amsterdam, Amsterdam, Netherlands.
  • Sarah van Zon
    Department of Gastroenterology and Hepatology, Amsterdam University Medical Centre, University of Amsterdam, Amsterdam, Netherlands.
  • Donghyeok Lee
    HORAIZON Technology BV, Delft, The Netherlands.
  • Colleen G C McGregor
    Translational Gastroenterology and Liver Unit, Nuffield Department of Medicine, University of Oxford and NIHR Oxford Biomedical Research Centre, Oxford, UK.
  • Melanie S Hulshoff
    Department of Gastroenterology and Hepatology, Amsterdam University Medical Centre, University of Amsterdam, Amsterdam, Netherlands.
  • Jack J Satsangi
    Translational Gastroenterology and Liver Unit, Nuffield Department of Medicine, University of Oxford and NIHR Oxford Biomedical Research Centre, Oxford, UK.
  • Wouter J de Jonge
    Tytgat Institute for Liver and Intestinal Research, Amsterdam Gastroenterology Endocrinology and Metabolism, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, The Netherlands.
  • Geert R D'Haens
    Department of Gastroenterology and Hepatology, Amsterdam University Medical Centre, University of Amsterdam, Amsterdam, Netherlands. Electronic address: g.dhaens@amsterdamumc.nl.